The dynamics of the glioma market are anticipated to change in the coming years owing to the positive outcomes of the emerging pipeline candidates during the developmental stage by key players, such as Bayer, VBL Therapeutics, Candel Therapeutics, AstraZeneca, DNAtrix, DelMar Pharmaceuticals, Chimerix, KaryoPharma, VBI Vaccines, Kazia Therapeutics, and others
LAS VEGAS, May 1, 2023 /PRNewswire/ -- DelveInsight's
Glioma Market Insights report includes a comprehensive understanding of current treatment practices, glioma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Glioma Market Report
As per DelveInsight analysis, the glioma market size in the 7MM was approximately
USD 1 billion in 2022.
According to the assessment done by DelveInsight, the estimated total incident glioma cases in the 7MM were approximately
47K in 2022.
Leading glioma companies such as
Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai and Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, VBI Vaccines, TME Pharma, Day One Biopharmaceuticals, Servier, Orbus Therapeutics, TVAX Biomedical, AnHeart Therapeutics, Beigene, SpringWorks Therapeutics, Forma Therapeutics, Hoffmann-La Roche, Incyte Corporation, Eli Lilly, and others are developing novel glioma drugs that can be available in the glioma market in the coming years.
The promising glioma therapies in the pipeline include
Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, Ofranergene Obadenovec (VB-111), LAM561 (2-OHOA), MEDI4736 (durvalumab), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), IGV-001, SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, SONALA-001 + Exablate 2.0 Device, VAL-083 (dianhydrogalactitol), Pomalidomide, MDNA55, BMX-001, Lenvatinib ± Pembrolizumab, Paxalisib (GDC-0084), OKN-007, Temferon, EO2401, INO-5401+ INO-9012+ LIBTAYO (cemiplimab), Selinexor (KPT-330), Olutasidenib (FT-2102), VBI-1901, NOX-A12 (Olaptesed Pegol), Tovorafenib (DAY101), Vorasidenib (AG-881), Eflornithine, TVI-Brain-1, AB-218, BGB-290, Mirdametinib, FT-2102 (Olutasidenib), Vinblastine + Bevacizumab, Cobimetinib, PEMAZYRE (Pemigatinib), VERZENIO (abemaciclib)
, and others.
In
December 2022, Chimerix announced the successful launch of the ONC201 Phase III ACTION study in patients with H3 K27M-mutant glioma.
In
June 2022, Day One Biopharmaceuticals announced positive initial data from its pivotal Phase II (FIREFLY-1) study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG).
Discover which therapies are expected to grab the major glioma market share @
Glioma Market Report
Glioma Overview
Glioma is the most common kind of glial cell tumor in the central nervous system (CNS). Gliomas are infiltrative tumors that affect the brain tissue surrounding them. Glioblastoma is the most hazardous type of brain tumor, whereas pilocytic astrocytomas are the least dangerous. Previously, diffuse gliomas were classified into subgroups and grades depending on histopathologies, such as diffuse astrocytomas, oligodendrogliomas, or mixed gliomas/oligoastrocytomas. The specific etiology of glioma, like other primary brain tumors, remains unknown. However, certain variables may increase the risk of getting a brain tumor. Glioma symptoms vary depending on tumor type, size, location, and growth rate. Some common glioma symptoms include headache, nausea or vomiting, memory loss, urine incontinence, speech problems, and others. A medical history and a physical examination are used for glioma diagnosis.
Glioma Epidemiology Segmentation
DelveInsight estimates that there were approximately
47K incident cases of glioma in the 7MM in 2022.
As per our analysis, the United States contributed to the largest incident population of glioma, acquiring
~40% of the 7MM in 2022.
The
glioma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total glioma incident cases
Glioma grade-specific cases
Glioma age-specific cases
Glioma type-specific cases
Download the report to understand which factors are driving glioma epidemiology trends @
Glioma Epidemiological Insights
Glioma Treatment Market
Glioma treatment is based on the type of glioma, its size and location, and the patient's unique characteristics. Chemotherapy and radiation therapy will be administered after surgery, particularly in individuals when the tumor cannot be removed entirely because it has invaded critical parts of the brain or is inaccessible. The typical glioma treatment protocol comprises
surgery, chemotherapy, and radiation. Chemotherapy may include
carmustine (BCNU), lomustine (CCNU), or gleostine (generic), cisplatin, carboplatin, etoposide, and irinotecan in case of low-grade glioma whereas
temozolomide (TEMODAR) is the standard chemotherapy used in case of high-grade glioma majorly,
Gliadel wafer implants (biodegradable discs injected with BCNU) are usually given as adjunctive treatment after surgery, although usage of Gliadel wafers remains a point of controversy due to its questionable survival benefits.
Avastin (Genentech) and Temodar/Temodal (Merck), among others, are approved medications for HGG. However, due to patent expiration, the generic version of Temodar and biosimilars of
Avastin are available on the glioma market. As generics and biosimilars are more cost-effective for patients than new medicines, intense competition exists among them. Furthermore, due to a lack of knowledge concerning bevacizumab's overall survival benefit, it is not recommended in unselected patients with newly diagnosed GBM. Currently, only one medication for LGG is approved,
Tafinlar (dabrafenib) plus Mekinist (trametinib).
Moreover, the current therapeutic market lacks a viable method for curing glioblastoma; therefore, the survival rate of people diagnosed with glioma remains poor. Glioma is incurable, and treatment choices are limited. Furthermore, the tumor has a high recurrence rate and a poor patient prognosis. In addition, there is currently no approved therapy for the unmethylated MGMT patient pool.
To know more about glioma treatment guidelines, visit @
Glioma Management
Glioma Therapies and Key Companies
Regorafenib: Bayer
ONC201: Chimerix
AV-GBM-1: Aivita Biomedical
Enzastaurin (DB-102): Denovo Biopharma
DCVax-L: Northwest Therapeutics
Ofranergene Obadenovec (VB-111): VBL Therapeutics
LAM561 (2-OHOA): Laminar Pharmaceuticals
MEDI4736 (durvalumab): MedImmune
Tasadenoturev (DNX-2401): DNAtrix
ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics
IGV-001: Imvax
SurVaxM: MimiVax
Berubicin: CNS Pharmaceuticals
GLIOVAC (Sitoiganap): Epitopoietic Research Corporation (ERC)
Lerapolturev + Pembrolizumab: Istari Oncology
SONALA-001 + Exablate 2.0 Device: SonALAsense
VAL-083 (dianhydrogalactitol): Kintara Therapeutics
Pomalidomide: Bristol Myers Squibb
MDNA55: Medicenna Therapeutics
BMX-001: BioMimetix
Lenvatinib ± Pembrolizumab: Eisai and Merck Sharp & Dohme
Paxalisib (GDC-0084): Kazia Therapeutics
OKN-007: Oblato
Temferon: Genenta Science
EO2401: Enterome
INO-5401+ INO-9012+ LIBTAYO (cemiplimab): Inovio Pharmaceuticals
Selinexor (KPT-330): Karyopharm Therapeutics
VBI-1901: VBI Vaccines
NOX-A12 (Olaptesed Pegol): TME Pharma
Tovorafenib (DAY101): Day One Biopharmaceuticals
Vorasidenib (AG-881): Servier
Eflornithine: Orbus Therapeutics
TVI-Brain-1: TVAX Biomedical
AB-218: AnHeart Therapeutics
BGB-290: Beigene
Mirdametinib: SpringWorks Therapeutics
FT-2102 (Olutasidenib): Forma Therapeutics
Vinblastine + Bevacizumab: Hoffmann-La Roche
Cobimetinib: Hoffmann-La Roche
PEMAZYRE (Pemigatinib): Incyte Corporation
VERZENIO (abemaciclib): Eli Lilly
Learn more about the FDA-approved drugs for glioma @
Drugs for Glioma Treatment
Glioma Market Dynamics
Glioma market growth can be ascribed to various factors, including an
aging population, evolving research, better diagnostic tests, developing surgical procedures, improved radiotherapy techniques, and novel systemic medicines.
Commercially, there is a
greater emphasis on high-grade glioma than low-grade glioma because patients with low-grade glioma often live longer than those with high-grade glioma. As a result, just a few
therapies are in late-stage studies, while the majority are in early-stage trials. In the case of GBM, on the other hand, the
pipeline is robust, with numerous potential therapies in late and mid-stage research that have yet to be marketed. The pipeline includes drugs with varied modes of action and administration routes. It is interesting to note that the emerging market of glioma includes budding gene therapy, i.e.,
ofranergene obadenovec (VB-111) by
VBL Therapeutics, followed by four vaccine/immunotherapy candidates such as
VBI-1901, AV-GBM-1 and ITI-1000 (pp65 DC Vaccine), tasadenoturev (DNX-2401) by
VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively, and these therapies are going to alter the glioma market dynamics in the upcoming years.
The current glioma market has been categorized based on the dominant treatment pattern across the 7MM, which shows slight variances in the overall prescription pattern. The forecast model considers
surgery, chemotherapy/radiation therapy, bevacizumab + radiotherapy/chemotherapy, and OPTUNE with temozolomide. The
anticipated launch of new therapies and
improved integration of early patient screening,
medication in secondary care and other clinical settings,
research on optimum implementation methods, and
increased awareness may eventually facilitate the development of successful treatment alternatives.
However, there are a few challenges to the
timely identification and treatment of these patients, such as a
lack of a reliable biomarker that can aid in diagnosis and patient classification and
identifying recurrence and
signaling medication response. Furthermore, the
failure rate of high-phased drug trials is significant, making it impossible to predict trial success, exacerbating the need for medicines that could assist ease the patient segment with this severe kind of cancer.
Scope of the
Glioma
Market Report
Therapeutic Assessment: Glioma current marketed and emerging therapies
Glioma
Market Dynamics: Conjoint Analysis of Emerging Glioma Drugs
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL's Views, Analyst's Views, Glioma Market Access and Reimbursement
Discover more about glioma drugs in development @
Glioma Clinical Trials
Table to Contents
Related Reports
Glioma Epidemiology Forecast
Glioma Epidemiology Forecast
– 2032 report delivers an in-depth understanding of the disease, historical and forecasted glioma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Glioma Pipeline
Glioma Pipeline Insight
– 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key glioma companies, including
PTC Therapeutics, Ono Pharmaceuticals, Philogen, SpringWorks Therapeutics, Xennials Therapeutics, AnHeart Therapeutics, Istari Oncology, among others.
High-Grade Glioma Pipeline
High-Grade Glioma Pipeline Insight
– 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key high-grade glioma companies, including
PTC Therapeutics, Aadi, Lee's Pharmaceutical, among others.
Malignant Glioma Pipeline
Malignant Glioma Pipeline Insight
– 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key malignant glioma companies, including
Bexion Pharmaceuticals, Inc., Lee's Pharmaceutical Limited, Merck & Co, Oblato, Inc., OncoSynergy, Inc, among others.
Recurrent Malignant Glioma Pipeline
Recurrent Malignant Glioma Pipeline Insight
– 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key recurrent malignant glioma companies, including
Bexion Pharmaceuticals, Inc., Merck, Oblato, OncoSynergy, Inc, among others.
Glioblastoma Pipeline
Glioblastoma Pipeline Insight
– 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key glioblastoma companies, including
AstraZeneca, BioNTech, Merck, Pfizer, Roche, among others.
Other Trending Reports
Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market
| Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market
Related Healthcare Services
Healthcare Consulting
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Connect with us on LinkedIn
|Facebook|Twitter
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
Logo:
SOURCE DelveInsight Business Research, LLP